A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 6, 2013, Pages 1343-1352

  Horsley, Laura ^a,h   Cummings, Jeff ^b   Middleton, Mark ^c   Ward, Tim ^b   Backen, Alison ^b   Clamp, Andrew ^a,h   Dawson, Martin ^b   Farmer, Hayley ^d   Fisher, Nita ^e   Halbert, Gavin ^f   Halford, Sarah ^d   Harris, Adrian ^c   Hasan, Jurjees ^a,h   Hogg, Philip ^g   Kumaran, Gireesh ^a,h   Little, Ross ^h   Parker, Geoff J M ^h   Potter, Paula ^a   Saunders, Mark ^a,h   Roberts, Caleb ^h   Shaw, Danielle ^a,h   Smith, Nigel ^b   Smythe, Jon ^e   Taylor, Andrew ⁱ   Turner, Helen ^d   Watson, Yvonne ^h   Dive, Caroline ^b   Jayson, Gordon C ^a,h   more..

^a CHRISTIE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^e JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^f UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

^h UNIVERSITY OF MANCHESTER   (United Kingdom)

ⁱ ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

Author keywords

Clinical trial; DCE MRI; GSAO; Novel arsenic compound; Phase 1

Indexed keywords

4 [N (S GLUTATHIONYLACETYL)AMINO]PHENYLARSENOXIDE; ARSENOSOBENZENE; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ANXIETY DISORDER; ARTICLE; BRADYCARDIA; BRAIN DISEASE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONFUSION; CONSTIPATION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG SAFETY; FATIGUE; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEIZURE; SINUS TACHYCARDIA; SOLID TUMOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ARSENICALS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUTATHIONE; HUMANS; INFUSIONS, INTRAVENOUS; LIVER FUNCTION TESTS; MAGNETIC RESONANCE IMAGING; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84890442259     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2320-9     Document Type: Article

References (25)

1. Brookes K, Cummings J, Backen A, Greystoke A, Ward T, Jayson GC, Dive C (2010) Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs. Br J Cancer 102:1524-1532
2. Cummings J, Langdon SP, Ritchie AA, Burns DJ, Mackay J, Stockman P, Leonard RC, Miller WR (1996) Pharmacokinetics, metabolism and tumour disposition of 8-chloroadenosine 3′,5′-monophosphate in breast cancer patients and xenograft bearing mice. Ann Oncol 7:291-296
3. Cummings J, Ranson M, Lacasse E, Ganganagari JR, St-Jean M, Jayson G, Durkin J, Dive C (2006) Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer 95:42-48
4. Cummings J, Ward TH, Lacasse E, Lefebvre C, St-Jean M, Durkin J, Ranson M, Dive C (2005) Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer 92:532-538
5. Dilda PJ, Decollogne S, Weerakoon L, Norris MD, Haber M, Allen JD, Hogg PJ (2009) Optimization of the antitumor efficacy of a synthetic mitochondrial toxin by increasing the residence time in the cytosol. J Med Chem 52:6209-6216
6. Dilda PJ, Don AS, Tanabe KM, Higgins VJ, Allen JD, Dawes IW, Hogg PJ (2005) Mechanism of selectivity of an angiogenesis inhibitor from screening a genome-wide set of Saccharomyces cerevisiae deletion strains. J Natl Cancer Inst 97:1539-1547
7. Dilda PJ, Ramsay EE, Corti A, Pompella A, Hogg PJ (2008) Metabolism of the tumor angiogenesis inhibitor 4-(N-(S-Glutathionylacetyl)amino)phenylarsonous acid. J Biol Chem 283:35428-35434
8. Don AS, Kisker O, Dilda P, Donoghue N, Zhao X, Decollogne S, Creighton B, Flynn E, Folkman J, Hogg PJ (2003) A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells. Cancer Cell 3:497-509
9. Ellerhorn M (1997) Ellenhorn's Medical Toxicology: diagnosis and treatment of human poisoning,. Williams & Wilkins
10. Greystoke A, Cummings J, Ward T, Simpson K, Renehan A, Butt F, Moore D, Gietema J, Blackhall F, Ranson M, Hughes A, Dive C (2008) Optimisation of circulating biomarkers of cell death for routine clinical use. Ann Oncol 19:990-995
11. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364
12. Hughes MF (2002) Arsenic toxicity and potential mechanisms of action. Toxicol Lett 133:1-16
13. Kramer G, Erdal H, Mertens HJ, Nap M, Mauermann J, Steiner G, Marberger M, Biven K, Shoshan MC, Linder S (2004) Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 64:1751-1756
14. Nordberg F, Nordberg Friberg ML (2007) Handbook on the toxicology of metals. AP/Elsevier, Amsterdam
15. Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K, Shinjo K, Fujita Y, Matsui H, Takeshita A, Sugiyama S, Satoh H, Terada H, Ohno R (2000) Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 133:881-885
16. Park D, Chiu J, Perrone GG, Dilda PJ, Hogg PJ (2012) The tumour metabolism inhibitors GSAO and PENAO react with cysteines 57 and 257 of mitochondrial adenine nucleotide translocase. Cancer Cell Int 12:11
17. Park D, Dilda PJ (2010) Mitochondria as targets in angiogenesis inhibition. Mol Aspects Med 31:113-131
18. Ramsay EE, Hogg PJ, Dilda PJ (2011) Mitochondrial metabolism inhibitors for cancer therapy. Pharm Res 28:2731-2744
19. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z, Wang ZY (1997) Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89:3354-3360
20. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell RP Jr (1998) Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339:1341-1348
21. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216
22. Tofts PS (1997) Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 7:91-101
23. Tsimberidou AM, Camacho LH, Verstovsek S, Ng C, Hong DS, Uehara CK, Gutierrez C, Daring S, Stevens J, Komarnitsky PB, Schwartz B, Kurzrock R (2009) A phase I clinical trial of darinaparsin in patients with refractory solid tumors. Clin Cancer Res 15:4769-4776
24. Waxman S, Anderson KC (2001) History of the development of arsenic derivatives in cancer therapy. Oncologist 6(Suppl 2):3-10
25. Westervelt P, Brown RA, Adkins DR, Khoury H, Curtin P, Hurd D, Luger SM, Ma MK, Ley TJ, DiPersio JF (2001) Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood 98:266-271